The research, conducted by Onda in Prince Edward Island, involved a trial in which Atlantic salmon were fed with varying concentrations of MycoFence prior to exposure to these pathogens.
Results indicated a substantial reduction in mortality rates for those salmon given higher MycoFence concentrations compared to a control group without β-glucan supplementation, pointing to a potent immunostimulatory effect of MycoFence that could decrease the reliance on antibiotics in aquaculture.
MycoFence was developed by Citribel, a Belgian biotech company that produces citric acid and mycelium. Using advanced technology, Citribel transforms fungal biomass into high-value ingredients for various industries.
